# US 2019/0172588 A1 · Pharmacogenetic drug interaction management system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0172588 A1
- Document ID: US20190172588A1
- Status: Published application
- Kind: A1
- Application number: 16/267,651
- Filed: 2019-02-05
- Published: 2019-06-06
- Earliest claimed: 2013-03-15
- Assignees: Bao Tran
- Inventors: Bao Tran; Ha Tran
- Web page: https://patentgrep.com/patent/US20190172588A1

## CPC

- G16H 50/30: for calculating health indices; for individual health risk assessment
- G06N 3/0464: Convolutional networks [CNN, ConvNet]
- G06N 3/09: Supervised learning
- G06N 20/00: Machine learning
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16H 15/00: ICT specially adapted for medical reports, e.g. generation or transmission thereof
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 70/40: relating to drugs, e.g. their side effects or intended usage
- G06N 3/045: Combinations of networks
- G06N 7/01: Probabilistic graphical models, e.g. probabilistic networks
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G06N: COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

A system is disclosed for personalized medical treatment based on biomarkers.

## Claims

### Claim 1

A system to provide information on a drug substance for a subject, comprising:
a network unit to receive gene or DNA sequencing data; and
a processor running:
code to match genomic biomarker(s) from gene or DNA sequencing for a population with historical information for a population on drug structure, dosage, clinical variability and risk for adverse events for the drug substance, the computer constructing side effect features for each drug, and applying a classifier to the features to predict one or more adverse drug interactions, the computer generating one or more indicia for the drug substance; and
code to apply the indicia to the subject DNA to provide personalized medicine.

### Claim 2 (depends on 1)

The system of claim 1, wherein the biomarkers comprise at least one of: germ-line or somatic gene variants, functional deficiencies, expression changes, chromosomal abnormalities, and protein biomarkers used to select patients for treatment.

### Claim 3 (depends on 1)

The system of claim 1, comprising indicia on gene, protein or chromosomal testing, genetic testing, functional protein assays, cytogenetic studies before using the drug and an indicia about changes in efficacy, dosage or toxicity due to genetic variants, an indicia on a gene or protein involved in the metabolism or pharmacodynamics of the drug, and an indicia that the gene or protein leads to different response.

### Claim 4 (depends on 1)

The system of claim 1, comprising a code communicating with: a gene-drug interactions training dataset that includes pharmaceutical and pharmacogenomics interactions for the drug; a side effect feature database for the drug from gene sensitivity associated with the drug; a gene-drug interactions classifier that predicts adverse gene-drug interactions for drug gene pairs and a subject's genetic scan; and for each of the side effects, a Fisher's exact test to determine predicted gene-drug-drug interactions.

### Claim 5 (depends on 1)

The system of claim 1, wherein the substance is a drug, comprising code for: constructing a gene-drug interactions training dataset that includes pharmaceutical, pharmacokinetic or pharmacodynamics, and pharmacogenomics drug-drug interactions for each drug; constructing side effect features for each of the plurality of drugs from side effects associated with the plurality of drugs; running a gene-drug-drug interactions classifier that predicts adverse drug-drug interactions for drug pairs and the genetic scan; and for each of the side effects, performing a Fisher's exact test to determine predicted gene-drug-drug interactions.

### Claim 6 (depends on 5)

The system of claim 5, wherein the gene-drug-drug interactions classifier uses a classifying objective function having a smoothness constraint and a fitting constraint to render the predicted adverse gene-drug interactions.

### Claim 7 (depends on 1)

The system of claim 1, comprising code for building a genetic drug-drug interactions classifier using deep learning with a neural network, comprising propagating drug-drug interactions between different ones of the plurality of drugs on a basis that if a first drug has an interaction with a second drug and the second drug is similar to a third drug, then the first drug is considered as having interaction with the third drug.

### Claim 8 (depends on 1)

The system of claim 1, wherein the indicia comprise a bar code, a near field communication (NFC) transmission, a text, or an Internet link.

### Claim 9 (depends on 1)

The system of claim 1, wherein the indicia is readable by a smart phone, comprising code to update the indicia with changes in the subject after the consumption of the substance.

### Claim 10 (depends on 1)

The system of claim 1, comprising a gene sequencer to capture genetic data from the subject, wherein the indicia is updated with changes in the subject after the consumption of the substance.

### Claim 11 (depends on 1)

The system of claim 1, comprising a module detect the evolutionary paths of escape

### Claim 12 (depends on 1)

The system of claim 1, comprising a hidden markov model (HMM) to detect evolutionary paths of escape.

### Claim 13 (depends on 1)

The system of claim 1, comprising a module to detect mutation by comparing later sequence reads by a genetic analyzer with prior sequence reads.

### Claim 14 (depends on 1)

The system of claim 1, comprising a module to detect an amount of mutation cancer polynucleotides in a sample from a subject over time by determining a frequency of the cancer polynucleotides at a plurality of time points; determining an error range for the frequency at each of the plurality of time points; determining, between an earlier and later time point, whether error ranges (1) overlap, indicating stability of frequency, (2) an increase at the later time point outside the error range, indicating increase in frequency or (3) a decrease at the later time point outside the error range, indicating decrease in frequency.

### Claim 15 (depends on 1)

The system of claim 1, comprising a model to infer tumor phylogeny from sequencing data, wherein subclones are related to each other by an evolutionary process of acquisition of mutations.

### Claim 16 (depends on 1)

The system of claim 1, comprising a deep learning machine using deep convolutionary neural networks for detecting genetic based drug-drug interaction.

### Claim 17 (depends on 1)

The system of claim 1, comprising code to:
acquire subject genetic scans using a gene sequencer;
identify each substance to be provided to the subject;
determine substance interactions for each drug and the genetic scan; and
provide indicia associated with each substance to warn the subject or a medical provider based on the genetic scan.

### Claim 18 (depends on 1)

The system of claim 1, comprising a module for analyzing a disease state of a subject by collecting genetic profile data on a population of tumors and original tumor treatment(s); identifying one or more evolutionary paths of escape and evolved tumor treatment(s); and based on a subject profile, predicting a probability of escape along the one or more evolutionary paths.

### Claim 19 (depends on 1)

The system of claim 1, comprising a module to recommend drug repurposing using drug-effect similarities from existing therapeutic indications of known drugs.

### Claim 20 (depends on 1)

The system of claim 1, comprising a module to predict side effects before a drug enters a clinical trial.
